Everest Medicines today announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals Hong Kong Limited (CORXEL).…
Browsing: Everest Medicines Limited
March 9, Everest Medicines (HKG: 1952) announced the commercial launch of VELSIPITY(R) (etrasimod arginine tablets) in Mainland China, highlighted by…
Everest Medicines today announced that China’s National Medical Products Administration (NMPA) has approved VELSIPITY(R) (etrasimod arginine tablets) for the treatment…
Everest Medicines (HKG: 1952, Everest, or the Company), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization…
Everest Medicines (HKG: 1952) today unveiled its 2030 strategy. Following the announcement, the Company’s shares strengthened during the trading session…
Everest Medicines announced on Dec. 11, 2025 that its wholly-owned subsidiary, Everest Medicines (China) Co., Ltd (Everest Medicines China), has…
Everest Medicines (HKG:1952) today announced that it has acquired an exclusive license with Visara, Inc. (Visara), a subsidiary of NovaBridge…
Everest Medicines today announced that the first patient has been enrolled in a global multi-center Phase I clinical trial of…
On August 29, Everest Medicines (HKG: 1952) announced its interim results for the six months ended June 30, 2025. The…
Everest Medicines today announced that etrasimod (VELSIPITY(R)) has been included in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults…
Everest Medicines (HKG: 1952.HK, Everest) today announced that the Taiwan Food and Drug Administration (TFDA) has officially accepted the New…
Everest Medicines (HKG: 1952) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON(R).…
Everest Medicines (HKG: 1952) today announced that the supplemental application for the production expansion of NEFECON® has been officially approved…
Everest Medicines (HKG: 1952) today announced a strategic equity investment in I-Mab (NASDAQ: IMAB), under which Everest will invest US$30.9…
Everest Medicines (HKG: 1952) today announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from…
Everest Medicines (HKG 1952, Everest, or the Company), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization…
– Officially Benefiting Mainland China Patients Everest Medicines (HKEX 1952.HK, Everest, or the Company), a biopharmaceutical company focused on the discovery,…
Officially Beginning to Benefit Asian Patients Everest Medicines (HKG: 1952, Everest, or the Company), a biopharmaceutical company focused on the…
Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical…
Everest Medicines (HKG: 1952, Everest, or the Company), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization…